Cognito Therapeutics to Present New Data Highlighting Effects of Spectris™ on Lipid Transport Biomarkers in Alzheimer’s Disease at AAIC 2026 Company to present data demonstrating increases in CSF ...

- Continued active treatment in the OVERTURE II OLE study demonstrated durability and preservation of brain structure and volume via MRI measurements over 18 months - Spectris™ treatment was well ...

Spectris AD™ meaningfully reduced functional and cognitive decline in Alzheimer’s Disease over 6 months compared to sham treatment and was associated with 60-84% time savings. OVERTURE I Phase 2 MRI ...

CAMBRIDGE, Mass., June 22, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced ...

Company to present data demonstrating increases in CSF HDL-like lipid transport proteins following Spectris therapy Cognito Therapeutics, a clinical-stage neurotechnology company developing ...